Drug Information

Drug (ID: DG01543) and It's Reported Resistant Information

• Name: Apalutamide
• Synonyms: Apalutamide; ARN-509; 956104-40-8; Erleada; ARN 509; JNJ-56021927; ARN509; Apalutamide (ARN-509); UNII-4T36H88UA7; 4-(7-(6-CYANO-5-(TRIFLUOROMETHYL)PYRIDIN-3-YL)-8-OXO-6-THIOXO-5,7-DIAZASPIRO[3.4]OCTAN-5-YL)-2-FLUORO-N-METHYLBENZAMIDE; 4T36H88UA7; 956104-40-8 (free base); 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide; 4-{7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl}-2-fluoro-N-methylbenzamide; Apalutamide [INN]; AR509; 4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluoro-N-methylbenzamide; ApalutamideARN509; Erleada (TN); JNJ 56021927; Apalutamide (JAN/INN); MLS006011109; SCHEMBL909297; GTPL9043; C21H15F4N5O2S; CHEMBL3183409; DTXSID40241899; EX-A089; QCR-211; HMS3656N12; AMY24182; BCP05829; AR509/AR-509; BDBM50094975; MFCD22380626; NSC771649; NSC794776; s2840; ZINC43174901; AKOS025401932; CCG-264760; CS-0885; DB11901; NSC-771649; NSC-794776; PB27306; NCGC00346725-01; NCGC00346725-02; NCGC00346725-06; 4-(7-(6-cyano-5-(trifluoroMethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspirooctan-5-yl)-2-fluoro-N-MethylbenzaMide; AC-27403; AS-35181; HY-16060; SMR004702891; SW220300-1; Y0375; 24872560, Erleada, C21H15F4N5O2S; D11040; J-519596; Q21098975; Benzamide, 4-[7-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl-
• Indication:
  In total 1 Indication(s)
  Discovery agent [ICD-11: N.A.]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Prostate cancer [ICD-11: 2C82]; [1]
• Target: Extracellular signal-regulated kinase 2 (ERK2); MK01_HUMAN; [1]
• Formula: 3
• IsoSMILES: CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F
• InChI: InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)
• InChIKey: HJBWBFZLDZWPHF-UHFFFAOYSA-N
• PubChem CID: 24872560
• TTD Drug ID: D08XVZ
• VARIDT ID: DR0121
• DrugBank ID: DB11901

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Prostate cancer [ICD-11: 2C82]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Androgen receptor (AR) [1]

• Molecule Alteration: Missense mutation; p.F877L (c.2629T>C)
• Resistant Disease: Prostate cancer [ICD-11: 2C82.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: LNCaP cells; Prostate; Homo sapiens (Human); CVCL_0395
• In Vitro Model: PC3 cells; Prostate; Homo sapiens (Human); CVCL_0035
• In Vivo Model: SHO male mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Chromatin immunoprecipitation assay
• Mechanism Description: The missense mutation p.F877L (c.2629T>C) in gene AR cause the resistance of Apalutamide by aberration of the drug's therapeutic target

Key Molecule: Androgen receptor (AR) [1]

• Molecule Alteration: Missense mutation; p.F877L (c.2629T>C)
• Resistant Disease: Prostate cancer [ICD-11: 2C82.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: LNCaP cells; Prostate; Homo sapiens (Human); CVCL_0395
• In Vitro Model: PC3 cells; Prostate; Homo sapiens (Human); CVCL_0035
• In Vivo Model: SHO male mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Chromatin immunoprecipitation assay
• Mechanism Description: The missense mutation p.F877L (c.2629T>C) in gene AR cause the resistance of Apalutamide by aberration of the drug's therapeutic target

Key Molecule: Androgen receptor (AR) [1]

• Molecule Alteration: Missense mutation; p.F877L (.
• Resistant Disease: Prostate cancer [ICD-11: 2C82.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: LNCaP cells; Prostate; Homo sapiens (Human); CVCL_0395
• In Vitro Model: PC3 cells; Prostate; Homo sapiens (Human); CVCL_0035
• In Vivo Model: SHO male mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Chromatin immunoprecipitation assay
• Mechanism Description: The missense mutation p.F877L (. in gene AR cause the resistance of Apalutamide by aberration of the drug's therapeutic target

References

• Ref 1: A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509Cancer Discov. 2013 Sep;3(9):1020-9. doi: 10.1158/2159-8290.CD-13-0226. Epub 2013 Jun 18.